Stomach Neoplasm Clinical Trials

42 recruitingLast updated: June 20, 2026

There are 42 actively recruiting stomach neoplasm clinical trials across 20 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3. Top locations include Seoul, South Korea, London, United Kingdom, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Stomach Neoplasm Trials at a Glance

42 actively recruiting trials for stomach neoplasm are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 2 with 18 trials, with the heaviest enrollment activity in Seoul, London, and Barcelona. Lead sponsors running stomach neoplasm studies include Asan Medical Center, Seagen, a wholly owned subsidiary of Pfizer, and Cancer Research UK.

Browse stomach neoplasm trials by phase

Treatments under study

About Stomach Neoplasm Clinical Trials

Looking for clinical trials for Stomach Neoplasm? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Stomach Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Stomach Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 42 trials

Recruiting
Phase 1

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Ovarian NeoplasmsStomach NeoplasmsLung Neoplasms+5 more
National Cancer Institute (NCI)100 enrolled1 locationNCT06885697
Recruiting

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

Stomach NeoplasmsMesotheliomaPancreatic Neoplasms+3 more
National Cancer Institute (NCI)1,000 enrolled1 locationNCT01950572
Recruiting
Phase 2Phase 3

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer

Stomach NeoplasmsSolid Tumor
SUNHO(China)BioPharmaceutical CO., Ltd.574 enrolled2 locationsNCT06504732
Recruiting
Phase 1

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Breast NeoplasmsCholangiocarcinomaOvarian Neoplasms+4 more
Eli Lilly and Company241 enrolled30 locationsNCT07213791
Recruiting
Phase 1

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Breast NeoplasmsStomach NeoplasmsColorectal Neoplasms+4 more
Eli Lilly and Company421 enrolled30 locationsNCT07114601
Recruiting
Not Applicable

PULSAR Combined With Immunotherapy for Unresectable Locally Advanced Gastric Cancer

Stomach NeoplasmsGastric AdenocarcinomaLocally Advanced Gastric Cancer+1 more
Samsung Medical Center53 enrolled1 locationNCT07607119
Recruiting

Rehabilitation and Recovery for Persons With Esophageal or Gastric Cancer

Esophageal CancerGastric CancerEsophageal Neoplasms+1 more
Region Skane100 enrolled1 locationNCT05698992
Recruiting
Not Applicable

Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial

Stomach NeoplasmsRobotic Surgical Procedures
First Affiliated Hospital of Wenzhou Medical University90 enrolled1 locationNCT07586384
Recruiting
Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled159 locationsNCT04389632
Recruiting
Phase 1Phase 2

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckOvarian Neoplasms+8 more
Cancer Research UK167 enrolled4 locationsNCT06380816
Recruiting
Phase 2

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled141 locationsNCT06157892
Recruiting
Phase 2

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Stomach NeoplasmsGastric Adenocarcinoma
Jinbo Yue54 enrolled1 locationNCT07007182
Recruiting

Identification of Therapeutic Targets in Metastatic Gastric Cancer

Stomach Neoplasms, Benign
Chinese University of Hong Kong100 enrolled1 locationNCT07551440
Recruiting
Phase 2

Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

Stomach NeoplasmsImmune Checkpoint Inhibitors
Xijing Hospital116 enrolled5 locationsNCT06576921
Recruiting
Phase 1

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Carcinoma, Non-Small Cell LungGastroesophageal Junction AdenocarcinomaStomach Neoplasms+3 more
Seagen, a wholly owned subsidiary of Pfizer914 enrolled44 locationsNCT06131840
Recruiting
Phase 2

A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer

Stomach Neoplasm
Asan Medical Center63 enrolled1 locationNCT05184803
Recruiting

Spanish Validation of KOQUSS-40 Questionnaire: Assessing QoL of Gastric Cancer Patients After Gastrectomy: SPQUSS-41

Stomach NeoplasmsValidation Study
Parc de Salut Mar505 enrolled6 locationsNCT07504913
Recruiting

Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies

Stomach NeoplasmsGastric NeoplasmsHelicobacter Pylori
University Hospital Center of Martinique112 enrolled1 locationNCT04949737
Recruiting
Not Applicable

Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer

Gastroesophageal-junction CancerStomach NeoplasmsEsophageal Neoplasms
Nurettin Şahin120 enrolled1 locationNCT07482566
Recruiting
Not Applicable

Argon Plasma Coagulation Versus Endoscopic Mucosal Resection for Gastric Adenoma (CLER-GA)

Stomach NeoplasmsPrecancerous ConditionsGastric Adenoma+1 more
Samsung Medical Center160 enrolled3 locationsNCT07161479